Literature DB >> 32446383

PLOD1, a target of miR-34c, contributes to cell growth and metastasis via repressing LATS1 phosphorylation and inactivating Hippo pathway in osteosarcoma.

Xiaolin Wu1, Hongfei Xiang1, Wenbin Cong2, Huiying Yang3, Guoqing Zhang1, Yan Wang1, Zhu Guo1, Yanqing Shen4, Bohua Chen5.   

Abstract

Although dysregulated PLOD1 was reported in many cancers, its function in osteocarcoma (OS) progression and potential mechanism are totally unknown. In the present study, we found that the mRNA expression of PLOD1 was significantly upregulated in OS cells and tissues. The high expression of PLOD1 was correlated with the aggressive phenotypes of OS and poor prognosis. Gain- or loss-of-function assays demonstrated that PLOD1 promoted proliferation, migration, and invasion of OS cells in vitro, as well as tumorigenicity and metastasis in vivo. We found that PLOD1 inactivated Hippo-YAP pathway through inhibiting phosphorylation-LATS1 (p-LATS1) and -YAP (p-YAP). Immunofluorescence results validated that nuclear distribution of YAP was increased by PLOD1 overexpression and was decreased by PLOD1 depletion. Furthermore, PLOD1 was demonstrated as a target of miR-34c, which inhibited the luciferase activity of PLOD1 mRNA 3'-UTR and PLOD1 expression at both mRNA and protein levels. The expression of miR-34c was downregulated in OS tissues and negatively correlated with PLOD1 mRNA expression. We found that restoration of PLOD1 abolished the miR-34c induced inhibition of cell growth and invasion. More importantly, miR-34c led to upregulation of p-LATS1 and p-YAP, and reducing of nuclear YAP and TAZ in OS cells. The mice tumors, which formed from miR-34c lentivirus vectors, have relatively low expression of PLOD1 and nuclear YAP staining. Taken together, our findings revealed that PLOD1 promoted tumorigenesis and metastasis in OS, and the dysregulated miR-34c/PLOD1/Hippo pathway affected OS progression, providing a potential therapeutic strategy for treatment.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Hippo-YAP; Metastasis; Osteosarcoma; PLOD1; miR-34c

Mesh:

Substances:

Year:  2020        PMID: 32446383     DOI: 10.1016/j.bbrc.2020.04.052

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  4 in total

1.  PLOD1 acts as a tumor promoter in glioma via activation of the HSF1 signaling pathway.

Authors:  Bo Yuan; Yimin Xu; Shaoqin Zheng
Journal:  Mol Cell Biochem       Date:  2021-11-29       Impact factor: 3.396

Review 2.  The Regulation of Collagen Processing by miRNAs in Disease and Possible Implications for Bone Turnover.

Authors:  Tomasz P Lehmann; Urszula Guderska; Klaudia Kałek; Maria Marzec; Agnieszka Urbanek; Alicja Czernikiewicz; Maria Sąsiadek; Paweł Karpiński; Andrzej Pławski; Maciej Głowacki; Paweł P Jagodziński
Journal:  Int J Mol Sci       Date:  2021-12-22       Impact factor: 5.923

3.  Potential prognostic markers and significant lncRNA-mRNA co-expression pairs in laryngeal squamous cell carcinoma.

Authors:  Junguo Wang; Dingding Liu; Yajun Gu; Han Zhou; Hui Li; Xiaohui Shen; Xiaoyun Qian
Journal:  Open Life Sci       Date:  2021-06-02       Impact factor: 0.938

4.  The relationship between PLOD1 expression level and glioma prognosis investigated using public databases.

Authors:  Lei Tian; Huandi Zhou; Guohui Wang; Wen Yan Wang; Yuehong Li; Xiaoying Xue
Journal:  PeerJ       Date:  2021-05-14       Impact factor: 2.984

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.